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Abstract. 
 
We have studied the biosynthesis and trans-
port of the endogenous caveolins in MDCK cells. We 
show that in addition to homooligomers of caveolin-1, 
heterooligomeric complexes of caveolin-1 and -2 are 
formed in the ER. The oligomers become larger, in-
creasingly detergent insoluble, and phosphorylated on 
caveolin-2 during transport to the cell surface. In the 
TGN caveolin-1/-2 heterooligomers are sorted into ba-
solateral vesicles, whereas larger caveolin-1 homooligo-
mers are targeted to the apical side. Caveolin-1 is 
present on both the apical and basolateral plasma 
membrane, whereas caveolin-2 is enriched on the baso-
lateral surface where caveolae are present. This sug-
gests that caveolin-1 and -2 heterooligomers are in-
volved in caveolar biogenesis in the basolateral plasma 
membrane. Anti–caveolin-1 antibodies inhibit the api-
cal delivery of influenza virus hemagglutinin without 
affecting basolateral transport of vesicular stomatitis vi-
rus G protein. Thus, we suggest that caveolin-1 homo-
oligomers play a role in apical transport.
 
C
 
aveolin
 
-1, a 21–24-kD membrane protein, was
originally isolated from two different sources:
from 
 
trans
 
-Golgi network–derived exocytic vesi-
cles (hence its other name VIP21, vesicular integral mem-
brane protein of 21 kD) (Kurzchalia et al., 1992), and from
plasma membrane invaginations called caveolae (Roth-
berg et al., 1992). Caveolae can be internalized from the
surface and the protein might cycle between different cel-
lular compartments (Parton et al., 1994; Schnitzer et al.,
1994), however, its functions are poorly understood thus
far. Caveolin-1 plays an important structural role in form-
ing caveolar invaginations on the plasma membrane (Fra
et al., 1995), but as yet there are no studies addressing its
function in the TGN. Caveolin-1 has two isoforms, 
 
a
 
- and
 
b
 
-derived from the use of two alternative transcription ini-
tiation sites, the latter starting with an internal methionine
at position 32 (Scherer et al., 1995). It has an unusual to-
pology, forming a membrane-embedded hairpin structure
with both the amino and carboxyl termini in the cytoplasm
(Dupree et al., 1993). Furthermore, it has been reported to
form high molecular weight homooligomeric complexes
(
 
.
 
10
 
4
 
 kD) that resolve into 200-, 400-, and 600-kD oligo-
mers when analyzed by SDS-PAGE without boiling (Mon-
ier et al., 1995; Sargiacomo et al., 1995). Caveolin-1 has
also been shown to bind tightly to cholesterol (Murata et
al., 1995; Li et al., 1996
 
b
 
). The primary determinants of oli-
gomerization are protein domains of caveolin-1, but cho-
lesterol binding promotes oligomerization that is further
stabilized by the attachment of palmitoyl chains to the car-
boxyl-terminal region (Monier et al., 1996). The oligomers
isolated from tissues or cultured cells are insoluble in de-
tergents, such as Triton X-100 or CHAPS at 4
 
8
 
C (Kurzchalia
et al., 1992; Sargiacomo et al., 1993). Oligomers can also
be produced from in vitro–synthesized caveolin-1 after
translocation into microsomal membranes. However, these
oligomers are Triton X-100 soluble (Monier et al., 1995).
Recently, a related protein having 38% sequence iden-
tity to caveolin-1 was isolated from caveolin-enriched mem-
branes and termed caveolin-2 (Scherer et al., 1996). Cave-
olin-2 was coexpressed with caveolin-1 in all the tissues
analyzed, being most abundant in adipocytes. The epitope-
tagged and overexpressed caveolin-2 colocalized with ca-
veolin-1 in fibroblasts, as judged by immunofluorescence
microscopy. However, in contrast to caveolin-1, caveolin-2
was found to exist mainly as a monomer (Scherer et al.,
1996).
MDCK epithelial cells are a well-characterized model
system for studying polarized membrane trafficking, and
are one of the sources from which caveolin-1 was first iso-
lated (Kurzchalia et al., 1992). These cells can form polar-
ized monolayers with distinct apical and basolateral sur-
faces. Sorting of proteins destined for the two plasma
membrane domains takes place in the TGN where sepa-
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rate apical and basolateral vesicles form to deliver cargo to
the correct destinations (Griffiths and Simons, 1986). In
this paper we have analyzed the routing and biochemical
characteristics of endogenous, newly synthesized caveolin-1
and -2 in MDCK cells. We provide evidence that the two
caveolins can form homo- and heterooligomeric complexes
in the ER, and that these complexes are modified during
transport to the plasma membrane. We further demon-
strate that large caveolin-1 complexes are present in apical
transport vesicles. In contrast, smaller caveolin-1/-2 het-
erooligomers are routed to the basolateral membrane
where caveolin-2 is enriched and caveolar structures are
found. Apical but not basolateral exocytosis can be inhib-
ited with caveolin-1 antibodies, suggesting that two different
caveolin complexes function in TGN to surface transport.
 
Materials and Methods
 
Reagents
 
Unless otherwise stated, all chemicals were obtained from the sources de-
scribed previously by Wandinger-Ness et al. (1990) and Ikonen et al.
(1995). The polyclonal anti–caveolin-1 amino-terminal antibody has been
characterized (Dupree et al., 1993) and the anti–caveolin-1 antibody des-
ignated N-20 was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
To generate anti–caveolin-2 antibodies, polyclonal sera were raised
against a synthetic peptide using the residues DFGDLEQLADSGSDR of
canine caveolin-2. Sera for biochemical experiments were affinity purified
using a GST-His6–caveolin-2 fusion protein (see Fig. 1; Peränen, 1992).
For immunofluorescence microscopy, sera were affinity purified on a col-
umn prepared by coupling the fusion protein to CNBr-activated–
Sepharose 4B or a protein A–Sepharose CL-4B column, according to the
manufacturer’s instructions (Pharmacia Biotech, Inc., Piscataway, NJ).
Antibodies were eluted at low pH (0.2 M glycine, pH 2.8). Molecular mass
standards used in gradient centrifugation were from Sigma Chemical Co.
(St. Louis, MO). Detergents were the following: SDS (Bio-Rad Laborato-
ries, Hercules, CA), Triton X-100 (Serva, Heidelberg, Germany), CHAPS
(Sigma Chemical Co.), and 
 
N
 
-octyl-3-
 
d
 
-glucopyranoside (Calbiochem-
Novabiochem, La Jolla, CA). Methyl-
 
b
 
-cyclodextrin was from Sigma
Chemical Co. and lovastatin was from Merck, Sharp, and Dohme (Haar,
Germany).
 
Cell Culture
 
MDCK strain II cells were grown on 1.2- (Western blotting, microscopy,
and transport assays), 2.4- (pulse-chase and metabolic labeling experi-
ments), or 7.5-cm (immunoisolation of vesicles) Transwell filters (Costar,
Cambridge, MA), as described previously (Pimplikar et al., 1994), plating 5
 
3
 
 10
 
4
 
, 2 
 
3
 
 10
 
5
 
, or 2 
 
3
 
 10
 
6
 
 cells per filter, respectively. The filter cultures
were maintained at 37
 
8
 
C and 5% CO
 
2
 
 for 3 or 4 d. MDCK strain II cells
stably expressing vesicular stomatitis virus glycoprotein (VSV-G)
 
1
 
–tagged
sialyltransferase were used in some experiments for release of TGN-derived
vesicles.
 
Cloning of Canine Caveolin-2 cDNA
 
For purification of canine caveolin-2, a detergent-insoluble fraction was
prepared from floated MDCK cell membranes and fractionated by affin-
ity chromatography on hydroxylapatite as described (Shevchenko et al.,
1997). Caveolin-2 was isolated by two-dimensional (2D) gel electrophore-
sis and then tryptic peptides from 50 Coomassie-stained spots were sub-
jected to Edman degradation. Total RNA was purified from MDCK cells
using the RNeasy kit (QUIAGEN, Inc., Santa Clarita, CA). Oligo-dT and
random primed cDNA generated with M-MLV reverse transcriptase
(Promega Corp., Madison, WI) was amplified by PCR with synthetic
oligonucleotides designed according to the human cDNA sequence
(5
 
9
 
-ATGGACGACGACTCCTACAGCCACCA-3
 
9
 
 and 5
 
9
 
-ACCATIARR-
CAIGTYTTIACRAANGGC-AT-3
 
9
 
) yielding a 334-bp fragment. With
this fragment, 360,000 clones of a 
 
l
 
ZAPII MDCK cDNA library were
screened. 12 independent positive phages were isolated containing inserts
of 1.5–2.3 kbp. Sequencing of the inserts revealed that none of the ob-
tained clones contained the full-length cDNA, therefore, 5
 
9
 
 RACE
(GIBCO BRL, Gaithersburg, MD) was performed using synthetic oligo-
nucleotides (5
 
9
 
-AACCCCTGCCGCGAAG-3
 
9
 
 and 5
 
9
 
-AAGGCCATGGG-
CATCGCCAGGAGCAAC-3
 
9
 
) for priming in reverse transcription and
amplification, respectively. The obtained 5
 
9
 
 end was then fused to the rest
of the coding sequence. The obtained full-length canine caveolin-2 se-
quence is available from GenBank/EMBL/DDBJ accession number
AF039223. A stable MDCK II cell line was established overexpressing ca-
veolin-2 with a carboxy-terminal myc epitope. The tag was introduced by
PCR and the cDNA was inserted in the expression plasmid pcDNA3 (In-
vitrogen, Carlsbad, CA). The DNA was transfected using electroporation
and stable clones were selected with 0.5 mg/ml G418 (GIBCO BRL). The
myc-tagged caveolin-2 was found in SDS-resistant oligomers to a similar
extent as the endogenous protein.
 
Labeling of Cells and Caveolin Immunoprecipitation
 
For pulse-chase experiments, cells were starved for 30 min at 37
 
8
 
C in me-
thionine-free medium before labeling with [
 
35
 
S]methionine (500 
 
m
 
mCi/fil-
ter) for 7 min. The cells were then either transferred to ice-cold chase me-
dium and lysed immediately, or chased at 20
 
8
 
C for 1 or 2 h or chased at
37
 
8
 
C for 1 or 2 h before lysis. A 2-h chase at 37
 
8
 
C gave results similar to a
1-h chase. In the cyclodextrin experiment (Scheiffele et al., 1997), cells
were chased for 1 h at 37
 
8
 
C before adding 10 mM methyl-
 
b
 
-cyclodextrin,
in chase medium containing 5 
 
m
 
M lovastatin and 50 mM Hepes, pH 7.4, to
both sides of the filter and incubating with shaking for 1 h at 37
 
8
 
C. A met-
abolic labeling was carried out for 18 h with 100 
 
m
 
Ci/filter [
 
35
 
S]methio-
nine. The compositions of the labeling and chase media have been de-
scribed previously (Wandinger-Ness et al., 1990).
For immunoprecipitation, cells were solubilized on ice in 20 mM Tris-
HCl, pH 7.4, 100 mM NaCl, 0.4% SDS, 0.2% Triton X-100 in the presence
of protease inhibitors (chymostatin, leupeptin, antipain, and pepstatin at
25 
 
m
 
g/ml each) and phosphatase inhibitors (200 
 
m
 
M sodium vanadate, 50
mM sodium fluoride). Lysates were incubated overnight at 4
 
8
 
C with the
respective antibody and recovered with protein A–Sepharose (Pharmacia
Biotech, Inc.). The immunoprecipitates were washed five times with 20
mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% SDS, 0.5% Triton X-100, and
phosphatase inhibitors (see above) and twice with 50 mM Tris-HCl, pH
7.5, before separation by SDS-PAGE.
For [
 
32
 
P], confluent MDCK cells from one 2.4-cm well of a six-well
plate were washed twice with phosphate-free DME containing 0.1% FCS
dialyzed against 20 mM Tris-HCl, pH 7.6, 137 mM NaCl (TBS).
After incubating for 50 min in this medium the cells were labeled for 3 h
at 37
 
8
 
C with 500 
 
m
 
Ci of 
 
g
 
[
 
32
 
P]ATP in 1 ml of the same medium. Cells were
lysed in 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1% Triton X-100, pro-
tease inhibitors, 2 mM sodium vanadate, and 50 mM sodium fluoride by
incubating for 20 min at 37
 
8
 
C with intermittent vortexing. After spinning
at 3,000 rpm in a microfuge (Eppendorf, Hamburg, Germany), the insolu-
ble debris was discarded, the lysates precleared with protein A–Sepharose
overnight at 4
 
8
 
C, and then precipitated with the anti–caveolin-1 antibody
as described above. [
 
35
 
S]methionine carried out overnight in an identical
well, and other treatments performed in parallel with the [
 
32
 
P] sample
gave results similar to the steady-state [
 
35
 
S]methionine and immunopre-
cipitation on filter-grown cells as described above. [
 
32
 
P] and [
 
35
 
S]methio-
nine was also carried out in 3T3 L1 preadipocytes, yielding results similar
to MDCK cells.
 
SDS-PAGE, 2D Gel Electrophoresis, and
Western Blotting
 
Immunoprecipitates were solubilized either in standard SDS-PAGE sam-
ple buffer or in alkaline buffer (Monier et al., 1995). The samples were in-
cubated for 30 min at 25
 
8
 
C or heated to 95
 
8
 
C for 5 min as detailed in the
figure legends. When the samples were not heated, 200-, 400-, and 600-kD
oligomers could be visualized by SDS-PAGE. The proteins were resolved
either on 13% linear or 3–17% gradient polyacrylamide gels. To dissoci-
ate the oligomers for 2D gel electrophoresis, immunoprecipitates were
heated at 95
 
8
 
C for 10 min in alkaline sample buffer (in the presence of 1 mM
vanadate), precipitated with chloroform/methanol, and then incubated at
37
 
8
 
C for 30 min in the isoelectric focusing sample buffer (Bravo, 1984).
 
1. 
 
Abbreviations used in this paper
 
: 2D, two-dimensional; HA, influenza
virus hemagglutinin; SLO, streptolysin-
 
O
 
; VSV-G, vesicular stomatitis vi-
rus glycoprotein. 
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Proteins were resolved as detailed by Wandinger-Ness et al. (1990) in two
dimensions by IEF and SDS-PAGE based on the method of Bravo (1984).
For Western blotting, MDCK cells were lysed in the same buffer as for
immunoprecipitations, incubated for 30 min at 25
 
8
 
C, and then proteins
were separated on polyacrylamide gels. Proteins were transferred to a ni-
trocellulose membrane in 25 mM Tris-HCl, 190 mM glycine, and 20%
methanol and after blocking and incubation with the respective antibodies
detected with enhanced chemiluminescence (Amersham Corp.).
 
Isolation of Budded Vesicles from Semiintact Cells
 
A budded fraction was prepared essentially as described by Xu and
Shields (1993) using a hypotonic swelling procedure to selectively disrupt
the plasma membrane (Beckers et al., 1987). Briefly, confluent MDCK
cells (passages 6–25) on 10-cm dishes infected with influenza virus (PR8)
or VSV were pulse labeled with [
 
35
 
S]methionine 3 h after infection and
then the radiolabeled glycoproteins were accumulated in the TGN by a
20
 
8
 
C temperature block for 2 h. After washing the cells three times with
ice-cold swelling buffer (10 mM Hepes [pH 7.2], 15 mM KCl) and incuba-
tion for 10 min on ice, cells were scraped in 3 ml of breaking buffer (50 mM
Hepes [pH 7.2], 90 mM KCl), pelleted at 800 
 
g
 
, and then washed once with
breaking buffer. Cells were resuspended in GGA buffer (25 mM Hepes,
[pH 7.4], 38 mM potassium gluconate, 38 mM potassium glutamate, 38 mM
potassium aspartate, 2.5 mM MgCl
 
2
 
, 0.5 mM CaCl
 
2
 
, 1 mM DTT, and pro-
tease inhibitors) and complemented with ATP regenerating system, 0.1 mM
GTP, 1 mg/ml rat liver cytosol. After incubation for 45 min at 37
 
8
 
C, cells
were pelleted in a microfuge at 6,000 
 
g
 
 and the budded fraction was either
analyzed directly by Western blotting or fluorography, or the sample was
adjusted to 30% Optiprep (Nycomed Pharma, Oslo, Norway), overlay-
ered with 25% Optiprep, 5% Optiprep, all in 10 mM Hepes (pH 7.4), 140
mM KCl, 2 mM EGTA, 1 mM DTT. The samples were centrifuged for 3 h
at 55,000 rpm in a TLS55 rotor (Beckman, Munich, Germany) and then
the vesicular fraction recovered from the 25%/5% interphase was ana-
lyzed by Western blotting, fluorography, or electron microscopy.
To determine release of the 
 
trans
 
-Golgi marker sialyltransferase from
cells, a cell line expressing VSV-G–tagged human sialyltransferase was es-
tablished and protein was detected by blotting with the monoclonal anti-
body P5D4 (Kreis, 1986) or immunoprecipitation.
 
Immunoisolation of Apical and Basolateral Vesicles
 
Immunoisolation of apical and basolateral vesicles from perforated
MDCK cells was carried out as detailed by Wandinger-Ness et al. (1990).
Briefly, filter-grown MDCK cells were labeled overnight with [
 
35
 
S]me-
thionine, infected with either influenza virus or VSV, and viral proteins
were accumulated in the TGN by a 20
 
8
 
C block. The cells were perforated
and membranes released during a 37
 
8
 
C incubation and then were floated
on a sucrose gradient. Apical and basolateral vesicles were immunoiso-
lated on cellulose fibers from the floated membrane fraction using anti-
bodies directed against influenza virus hemagglutinin (HA) and VSV-G,
respectively. Proteins were recovered from the fibers in 0.4% SDS, 0.2%
Triton X-100 in TNE, and then loaded on a 5–30% sucrose gradient (see
below). Caveolin complexes were immunoprecipitated from the fractions
with anti–caveolin-1 antibodies and the radioactivity recovered in each
fraction was counted in a liquid scintillation counter (Wallac 1410; Phar-
macia Biotech, Uppsala, Sweden).
 
Sucrose Gradient Centrifugation
 
Cell lysates or immunoisolated vesicles (300 
 
m
 
l) in 0.4% SDS, 0.2% Triton
X-100, and protease inhibitors (see above) were loaded onto a linear
5–30% sucrose gradient in 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.4%
SDS, 0.2% Triton X-100. After centrifugation in a SW60 rotor (Beckman)
for 16 h at 45,000 rpm, 500 
 
m
 
l fractions were collected from the top. For
Western blot analysis, proteins were TCA precipitated or immunoprecipi-
tated with anti–caveolin-1 antibodies in the case of labeled samples. Pro-
teins were resolved on gradient polyacrylamide gels.
 
CHAPS Extraction
 
After pulse-chase labeling, the cells were scraped on ice in 500 
 
m
 
l of 20 mM
CHAPS in 50 mM Tris-HCl, pH 7.0, 100 mM NaCl, 1 mM EDTA (TNE)
in the presence of protease and phosphatase inhibitors (see above). After
resuspension 10 times with a 1-ml pipet tip, they were incubated on ice for
30 min, and CHAPS-insoluble material was pelleted by centrifugation in a
TLA45 rotor (Beckman) for 30 min at 45,000 rpm and 4
 
8
 
C. The superna-
tant was collected and the pellet resuspended in CHAPS extraction
buffer. 4 vol of 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5% SDS, and
protease and phosphatase inhibitors (see above) were added and caveolin
complexes immunoprecipitated.
 
In Vitro Transport Assays
 
The transport of VSV-G and HA in streptolysin 
 
O
 
 (SLO)-permeabilized
MDCK cells was carried out exactly as described previously (Pimplikar et al.,
1994; Ikonen et al., 1995; for review see Lafont et al., 1995). Briefly, to
measure TGN-to-surface transport, filter-grown MDCK cells were in-
fected with VSV or influenza virus, viral proteins were pulse labeled with
[
 
35
 
S]methionine, and then chased to the TGN using a 20
 
8
 
C incubation.
The apical or basolateral cell surface was then permeabilized with SLO,
the endogenous cytosol was depleted, and transport to the intact surface
reconstituted. The amount of viral proteins reaching the surface was mea-
sured by trypsinization (HA) or surface immunoprecipitation (VSV-G).
To measure transport from the ER, the 20
 
8
 
C-chase was omitted and SLO
permeabilization was carried out immediately after pulse labeling. The
amount of viral proteins reaching the Golgi complex was determined by
endoglycosidase H digestion. The anti–caveolin-1 amino-terminal anti-
body N-20 was used at a final concentration of 10 
 
m
 
g/ml. Before raising
the temperature to 37
 
8
 
C to initiate transport, the cells were incubated for
30 min at 4
 
8
 
C with cytosol 
 
6
 
 antibody and an ATP regenerating system.
Quantitation of viral polypeptides resolved by SDS-PAGE was done with
a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA). Transport
without added cytosol was defined as 0% and transport in the presence of
cytosol as 100%, being 2.5–4.5-fold higher than without cytosol. The val-
ues obtained in the presence of antibodies were expressed as a percentage
of those given without antibody addition. All transport assays were per-
formed in triplicate and each condition was tested at least twice.
 
Immunofluorescence Microscopy
 
Filter-grown, confluent MDCK cells were rinsed once in PBS and then
fixed for 10 min in 4% paraformaldehyde/PBS. The filters were rinsed
briefly in PBS, cut from the holder, and then incubated for 30 min in 200
mM glycine/PBS. They then were incubated for 10 min in 0.1% Triton
X-100/PBS and nonspecific antibody binding was blocked by incubating
for 10 min in PBS containing 0.2% cold-water fish skin gelatin (PBS-G).
The filter pieces were incubated for 2 h with either affinity-purified rabbit
anti–caveolin-1 antibodies (N20) diluted 1:25 or rabbit anti–caveolin-2 an-
tibodies diluted 1:10 in PBS-G. After extensive rinsing (more than six times
at 5-min each) the filterpieces were incubated for 1 h at 37
 
8
 
C with fluores-
cein thiocyanate coupled anti-rabbit antibodies in PBS G. After extensive
rinsing in PBS, the filter pieces were embedded in 50% glycerol, 100 
 
m
 
g/ml
1,4-diazobi-cyclo(2,2,2)-octane in PBS, and then examined under a confocal
scanning light microscope (LSM410; Carl Zeiss, Inc., Thornwood, NY).
 
Immunoelectron Microscopy
 
Filter-grown confluent MDCK cell were rinsed once in PBS and fixed for
10 min in 4% paraformaldehyde/PBS. Triangular filter pieces in PBS were
progressively infiltrated with gelatin at 37
 
8
 
C to a final concentration of
10%. They were put on ice and infiltrated with 2.1 M sucrose. The filter
pieces were put on top of a cryosectioning stub and frozen in liquid nitro-
gen. Ultrathin cryosections were collected on grids and incubated face-
down in PBS for 30 min at 37
 
8
 
C to dissolve the gelatin. The grids were
transferred for 30 min to 10% FCS in PBS and then incubated for 1 h with
affinity-purified rabbit anti–caveolin-1 antibodies (N20) diluted 1:20 or
rabbit anti–caveolin-2 antibodies diluted 1:10 in 5% FCS in PBS. The
grids were rinsed in PBS and incubated for 20 min with protein A–coupled
10-nm gold particles in 5% FCS in PBS. The grids were rinsed extensively
with PBS and tridistilled water and then incubated for 10 min with 0.3%
uranyl acetate, 1.8% methylcellulose in tridistilled water on ice. Excess
fluid was removed and then the grids were air-dried. Sections were exam-
ined under a Zeiss EM1OC transmission electron microscope.
For immunolabeling of isolated vesicles, small droplets (1–2 
 
m
 
l) of the
vesicle preparation were put on top of formvar and carbon-coated copper
grids for 5 min. They were then fixed on top of a drop of 4% paraformal-
dehyde (PFA) in PBS for 5 min. After blocking with 200 mM glycine in
PBS for 10 min and a 5-min wash in PBS containing 0.5% BSA and 0.2%
cold-water fish skin gelatin (PBG), the grids were incubated for 15 h with
the first primary antibody in PBG at 4
 
8
 
C. After a 3–5-min rinse in PBG,
the grids were incubated with protein A–coupled 15-nm gold particles in
PBG for 1 h and then rinsed in PBS. In a second (5 h at room tempera- 
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ture) and third (15 h at 4
 
8
 
C) round of immunoincubation, the sequence of
labeling was repeated from the fixation to the washing in PBS. In the sec-
ond and third round, protein A coupled to 10- and 5-nm gold particles
were used, respectively. After the third round of labeling, the grids were
rinsed in tridistilled water and then incubated for 5 min on ice in 0.3%
uranyl acetate, 1.8% methylcellulose in tridistilled water. The excess fluid
was removed and the grids were air-dried. Controls included the omission
(of combinations) of primary antibodies after which the accompanying
gold particles were not detected. For quantitations, routinely gold parti-
cles on 40 individual vesicles were counted. Vesicles were considered pos-
itive for the viral marker proteins when they contained at least two parti-
cles. In individual experiments similar results were obtained independently,
in which the order of the antigens was labeled with the antibodies.
 
Results
 
A New Protein Coprecipitates with
Caveolin-1 Antibodies
 
Antibodies raised against the first 20 amino-terminal amino
acids of caveolin-1 recognize a single band of 
 
z
 
24-kD by
Western blotting, corresponding to the 
 
a
 
 isoform of caveo-
lin-1 (Dupree et al., 1993). However, these antibodies im-
munoprecipitate proteins that are resolved as two bands of
 
z
 
21- and 24-kD, respectively, in SDS-PAGE (Dupree et
al., 1993, Fig. 1 
 
A
 
). So far, these bands have been thought
to represent 
 
a
 
– and 
 
b
 
–caveolin-1 (Monier et al., 1995).
Surprisingly, when the immunoprecipitates were analyzed
on a 2D gel, other spots in addition to the ones known to
correspond to 
 
a
 
– and 
 
b
 
–caveolin-1 were revealed. By far,
most abundant was a cluster of spots that corresponded in
size to 
 
b
 
–caveolin-1 but had a more acidic isoelectric point
(Fig. 1 
 
B
 
). When comparing this pattern to the 2D gel
maps of immunoisolated apical and basolateral transport
vesicles, we found that this elongated pattern corre-
sponded exactly to a protein heavily enriched in basolat-
eral transport vesicles that was designated B12 (Fig. 1, 
 
C
 
and 
 
D
 
; Wandinger-Ness et al., 1990).
 
Cloning of Canine Caveolin-2 cDNA
 
To identify this protein potentially associating with caveo-
lin-1, a detergent-insoluble fraction of floated MDCK cell
membranes was prepared, separated by affinity chroma-
tography on hydroxylapatite as described (Shevchenko
et al., 1997), and the protein was isolated from 2D gels for
microsequencing. The obtained peptide sequences (X-S-
A-V-D-F-G-X-L-E-Q and X-F-S-S-V-X-L-Q/L-V, see Fig.
2 
 
D
 
) suggested that the protein was caveolin-2. A partial
canine caveolin-2 cDNA was then amplified using degen-
erate oligonucleotides derived from the human caveolin-2
cDNA sequence (Scherer et al., 1996) and used to screen a
 
l
 
ZAPII MDCK cDNA library. 5
 
9
 
-RACE revealed that the
ATG corresponding to the published initiator methionine
in the highly homologous human caveolin-2 was preceded
by an in-frame methionine, 13 amino acids further up-
stream (Fig. 2 
 
D
 
). The sequences flanking this ATG con-
form better to the Kozak consensus than those around the
downstream ATG, suggesting that it may be used as the
preferential initiator site. Moreover, database searches re-
vealed a human expressed sequence tag (THC180343; Gen-
Bank/EMBL/DDBJ accession number AA367026) that also
carries the upstream start codon. As the amino-terminal
part was most divergent between caveolin-1 and -2, we
used a peptide containing amino acids 26–40 as an immu-
nogen to raise canine caveolin-2–specific antibodies (Fig. 2
 
D). In Western blotting this antibody was found to recog-
nize two proteins of 19- and 21-kD, both distinct from a–cav-
eolin-1 (Fig. 2, A and B). On 2D gels, the elongated group
of spots representing B12 was detected (Fig. 2 C). In addi-
tion, the caveolin-2 antibodies cross-reacted with a cluster
of spots of similar shape but of smaller size (z19 kD, Fig. 2
C). These were found to correspond to minor spots be-
neath the original band cut for microsequencing (refer to
Fig. 1 B). Based on the sequence information, it is likely to
represent the product of a transcript using methionine 14
as an alternative, less favored site for initiation. Clearly,
the anti–caveolin-2 antibodies were specific for these two
rows of spots and did not cross-react with a– and b–cav-
eolin-1.
Caveolin-2 Is Present in a Large Oligomeric Complex
Based on their sequence similarity, caveolin-2, like caveo-
lin-1, would be predicted to form high molecular weight
complexes. Unexpectedly, the epitope-tagged overexpressed
human caveolin-2 was found to exist preferentially as a
monomer (Scherer et al., 1996). To find out if endogenous
canine caveolin-2 is present in stable oligomers, we ap-
plied the same technique as used previously for human ca-
veolin-1 (Monier et al., 1995), taking advantage of the sta-
bility of the oligomers in SDS and 2-mercaptoethanol. The
high molecular weight proteins in the MDCK cell lysate
were separated by SDS-PAGE and then analyzed by
Western blotting using caveolin-1 and -2–specific antibod-
ies. Fig. 3 A shows that both caveolins resolved into 200-,
400-, and 600-kD complexes. To further characterize the
oligomers, we developed a fractionation technique that
Figure 1. Caveolin-1 and -2
in MDCK cells. Anti–caveo-
lin-1 immunoprecipitates were
analyzed by 13% SDS-PAGE
(A) and by 2D gel electro-
phoresis (B). For compari-
son, 2D gels of immunoiso-
lated basolateral (C) and
apical (D) vesicles are shown.
a– and b–caveolin-1 are
marked by arrowheads. Ca-
veolin-2 is marked by arrows.
Filter-grown MDCK cells
metabolically labeled with
[35S]methionine were lysed
and then caveolin was immu-
noprecipitated using anti–
caveolin-1 amino-terminal
antibodies. The samples were
boiled in alkaline sample
buffer before electrophoresis.Scheiffele et al. Caveolin-1 and-2 in MDCK Cells 799
separated the complexes into several size classes. This was
based on sedimentation velocity centrifugation in a sucrose
gradient in the presence of SDS and Triton X-100 (refer to
Materials and Methods). When a MDCK cell lysate was
analyzed by this method and the caveolins visualized by
immunoblotting with both anti–caveolin-1 and -2, we found
that some of the oligomers migrated to the middle of the
gradient (corresponding to z200–400-kD), whereas others
sedimented as very large complexes (.600 kD) (Fig. 3 B).
All complexes contained both caveolin-1 and -2. However,
the large complexes contained significantly less caveolin-2
than the 200–400-kD oligomers. The vast majority of the
other cellular proteins were detected in the first four frac-
tions of the gradient (data not shown).
To estimate the stoichiometry of caveolin-1 and -2 in the
caveolin complexes, the immunoprecipitations were per-
formed after an overnight metabolic labeling (Fig. 4). The
precipitated proteins were analyzed by 2D gelelectro-
phoresis and then the intensities of the 2D gel spots were
quantitated by Phosphor Imager analysis (as caveolins-1
and -2 contain five or six methionine residues, respec-
tively, incorporated radioactivity should represent approx-
imately equivalent amounts of each protein). In the case of
anti–caveolin-1 antibodies, the ratio was about 2:2:1 for
a–caveolin-1/b–caveolin-1/caveolin-2 (summing the ma-
jor 21- and minor 19-kD spots of caveolin-2) (Fig. 4, top).
On the other hand, anti–caveolin-2 antibodies precipitated
the proteins in the ratios of about 1:1:1 (one molecule of
a– and one of b–caveolin for every caveolin-2 molecule)
(Fig. 4, bottom). These findings demonstrate that there is
about two times more caveolin-1 than -2 in the complexes at
steady  state. This could result from two different com-
plexes, one type containing only caveolin-1 and another
containing both caveolins.
Modification of the Caveolin Complexes during 
Biosynthetic Transport
Our data suggest that caveolin-1 and -2 form oligomeric
complexes in MDCK cells. To follow the formation and in-
tracellular transport of these complexes, we decided to an-
alyze the properties of the newly synthesized caveolins in a
pulse-chase protocol using anti–caveolin-1 antibodies. As
shown above, this protocol also brings down caveolin-2.
The proteins were labeled with a 7-min pulse of [35S]me-
thionine and (a) directly cooled on ice and processed for
analysis, (b) chased for 1 or 2 h at 208C, or (c) chased for 1
or 2 h at 378C before analysis. The 208C samples represent
the complexes present in the Golgi complex after the 208C
chase. The bulk of the pulse-labeled caveolins were local-
ized in a density gradient fraction containing the trans-
Golgi marker sialyltransferase (data not shown).
Figure 2. Specificity of the anti–caveolin-2 antibody. A MDCK
cell lysate separated by SDS-PAGE (A and B) or by 2D gel elec-
trophoresis  C  was analyzed by Western blotting. Blots were
probed with anti–caveolin-1 amino-terminal antibodies (A) or
with anti–caveolin-2 antibodies (B and C). The two spots identi-
fied in C correspond to two clusters of spots detected in the 2D
gel of [35S]methionine and immunoprecipitated samples (refer to
Fig. 1). The larger cluster has the same molecular weight as the
spot cut for microsequencing. The 59 cDNA sequence of canine
caveolin-2 and the encoded amino acids are aligned with the hu-
man expressed sequence tag containing the upstream ATG
codon (D). The sequence of a tryptic peptide is underlined. The
peptide used to raise anti–caveolin-2 specific antibodies is indi-
cated by a box.
Figure 3. Caveolin-2 forms high molecular weight complexes.
Western blotting using anti–caveolin-1 antibody N-20 or anti–
caveolin-2 antibodies was performed after separating MDCK cell
lysate on SDS-PAGE without boiling (A). Alternatively, the cell
lysate was first fractionated by sedimentation velocity in a 5–30%
sucrose gradient, and TCA proteins precipitated from the frac-
tions were separated by 13% SDS-PAGE after boiling in alkaline
sample buffer (B). The migration of molecular mass standards in
the gradient is indicated.
Figure 4. Composition of the caveolin oligomeric complex at
steady state. MDCK cells were labeled overnight with [35S]me-
thionine, proteins were immunoprecipitated with caveolin-1 (top)
or -2 antibodies (bottom), and then analyzed by 1- (left) or 2D gel
electrophoresis (right) after boiling in alkaline sample buffer. The
anode is to the right. For quantification of the relative amounts of
caveolin-1 and -2, gels were scanned by a Phosphor Imager.The Journal of Cell Biology, Volume 140, 1998 800
Protein Composition of the Complexes. The results shown
in Fig. 5 suggest that a heterooligomeric complex is formed
already in the ER, as both anti–caveolin-1 (Fig. 5, A–C)
and -2 antibodies (data not shown) brought down both of
the proteins in all conditions tested. The relative propor-
tions of the two proteins did not seem to change signifi-
cantly during biosynthetic transport, except for slightly
more caveolin-2 being precipitated without chase (in the
ER) than in the other conditions (compare Fig. 5 A to B
and C).
This data also demonstrates that the efficiency of immu-
noprecipitation is low in the ER (z10%, assuming that a
constant amount of protein is present throughout the
pulse-chase protocol), whereas the antibody brings down
the proteins quantitatively at steady state. This was also
evident in a previous report (Monier et al., 1995), and
could be because of conformational changes in the epitope
or more efficient precipitation of higher oligomers versus
monomers or dimers (see below).
Size of the Complexes. To monitor changes of the com-
plex sizes, pulse-labeled proteins were subjected to frac-
tionation in the SDS–Triton X-100 sucrose gradient followed
by immunoprecipitation with anti–caveolin-1 antibodies.
The newly synthesized caveolins were monomeric (Fig. 6
A, fractions 2 and 3), but a sizeable fraction had already
oligomerized forming a SDS–Triton X-100 stable complex
of z200 kD (Fig. 6 A, fractions 5 and 6). Taking into ac-
count the inefficient precipitation of the monomers in the
ER, a cautious quantitative assessment would be that in
the ER at least ten times more of the protein exists as a
monomer than as oligomer. Nevertheless, oligomerization
obviously starts early in the biosynthetic route. When the
proteins were chased for 1 h at 208C, i.e., when most of the
newly synthesized proteins resided in the Golgi apparatus,
the caveolin complex increased in size, peaking at z400-kD
with some already extending to the 600-kD range (Fig. 6
B). When performed at 378C, most of the protein was
chased to the cell surface; the caveolin oligomers matured
further to higher molecular weight complexes, reaching
the size range of the very large structures detected at
steady state (Fig. 6 C). It is noteworthy that the choice of
detergent in the gradient is critical to observe the size
changes.  N-octyl-3-d-glucopyranoside (octylglucoside) has
previously been used in comparable size fractionation
schemes and reported to detect oligomers between 200–
400-kD, irrespective of the conditions (Li et al., 1996b;
Monier et al., 1996). In our experience, when SDS and Tri-
ton X-100 were replaced with octylglucoside, a similarly
sized 200–400-kD oligomer was detected either in the ER
or on the plasma membrane (data not shown). Therefore,
the observed complex sizes do not necessarily reflect the
molecular weight of the oligomers in vivo; however, they
clearly demonstrate changes in size and nature of the com-
plexes during biosynthetic transport. The maturation is
likely to be achieved not only by protein–protein interac-
tions, but might also be influenced by the lipid environ-
ment. This could explain why the choice of detergent and
its capability to dissociate or preserve such protein–lipid
complexes is critically influencing the resolved complex
sizes.
Cholesterol has been demonstrated to promote homo-
oligomerization in microsomes (Monier et al., 1996) and
could regulate the oligomer size in vivo. The membrane
cholesterol level is low in the ER and increases along the
exocytic route towards the plasma membrane. We chased
the pulse-labeled proteins to the cell surface (1 h at 378C)
and then incubated the cells with methyl-b-cyclodextrin to
extract plasma membrane cholesterol. Indeed, this treat-
ment (causing the removal of >50% of cellular choles-
terol; Rietveld, A.G., and K. Simons, personal communi-
cation) resulted in a decrease in size of the caveolin oligomers
from the one typical for the plasma membrane to a size
corresponding to the Golgi form (Fig. 6 D). It is important
to note that under these conditions, the intracellular local-
ization of caveolin-1 is not significantly changed as judged
by immunofluoresence analysis (data not shown).
Phosphorylation of the Complexes. One striking observa-
tion from the 2D gel analysis of the caveolin complexes is
that the number of spots corresponding to caveolin-2 in-
Figure 5. Analysis of the ca-
veolin complex by 2D gel
electrophoresis during bio-
synthetic transport. MDCK
cells were pulse labeled with
[35S]methionine for 7 min
and either lysed immediately
(A), chased for 1 h at 208C
(B) or chased for 1 h at 378C
(C) before lysis. Alterna-
tively, cells were labeled for
3 h with [32P]ATP (D). The
caveolin complex was immu-
noprecipitated by anti–cave-
olin-1 antibodies and then
analyzed on 2D gels.
Figure 6. Size of the caveolin
oligomeric complexes during
biosynthetic transport and af-
ter cyclodextrin treatment.
Filter-grown MDCK cells were
pulse labeled for 7 min with
[35S]methionine and then
chased as indicated in A, B,
and  C. When cyclodextrin
was added (1 CD), MDCK
cells, pulsed for 7 min with
[35S]methionine and chased
for 1 h at 378C, were treated
for an additional 1 h at 378C
in the presence of 10 mM
methyl-b-cyclodextrin as de-
tailed in Materials and Meth-
ods. The lysates were frac-
tionated by sedimentation
velocity gradient centrifuga-
tion in 5–30% sucrose and
caveolin immunoprecipitated
from the fractions using anti–
caveolin-1 amino-terminal anti-
bodies. The intensities of the
bands resolved by SDS-PAGE (containing caveolin-1 and -2)
were scanned by a Phosphor Imager. The percentage of caveolin
in each fraction is presented as bars.Scheiffele et al. Caveolin-1 and-2 in MDCK Cells 801
creases during transport to the cell surface, with one extra,
more acidic spot in the Golgi complex (Fig. 5 B) and two
after 1 h at 378C (delivery to the cell surface) (Fig. 5 C).
Furthermore, this modification is extensive at steady state,
producing up to four adjacent spots of the longer and
three of the shorter form of caveolin-2 (Fig. 4). We as-
sumed that these modifications causing an increase in neg-
ative charge without changing the apparent molecular
weight could be phosphorylations, and therefore, we per-
formed metabolic labelings with [32P]ATP in parallel with
[35S]methionine. After [32P] and immunoprecipitation with
anti–caveolin-1, antibodies samples were separated on 2D
gels. This analysis showed that in steady-state conditions,
caveolin-2 is indeed heavily phosphorylated, whereas ca-
veolin-1 is not (Fig. 5 D).
Detergent Solubility. Caveolin-1 is known to be insoluble
in the detergents Triton X-100 and CHAPS at 48C, both in
TGN-derived transport vesicles and in plasma membrane
caveolae, whereas it is soluble when inserted into mi-
crosomes in vitro (Kurzchalia et al., 1992; Melkonian et al.,
1995; Monier et al., 1995). To find out when this change
occurs during biosynthetic transport, we analyzed the solu-
bility of the caveolin complexes during a pulse-chase ex-
periment. The oligomer was found to be entirely soluble
immediately after the pulse labeling, and two-thirds of it
still remained soluble after a 1-h chase at 208C (Fig. 7).
When the chase at 208C was extended to 2 h, three-fourths
of the complex had become CHAPS insoluble. If the pro-
tein was allowed to proceed along the biosynthetic route
at 378C, a 1-h chase was sufficient to convert it to a form
resisting CHAPS solubilization as efficiently as the protein
did at steady state (>90% being CHAPS insoluble). Simi-
lar changes in the detergent solubility of the caveolin com-
plex were observed when Triton X-100 was used at 48C in-
stead of CHAPS (data not shown). These data suggest that
only after reaching the Golgi complex do caveolins be-
come increasingly resistant to detergent extraction.
Different Caveolin Complexes Exist in Apical and 
Basolateral Vesicles
The selective recovery of caveolin-2 in immunoisolated
basolateral carriers (Fig. 1) suggests that the caveolin com-
plexes exiting the TGN along the apical and the basolat-
eral routes may have different compositions. We fraction-
ated metabolically labeled apical and basolateral vesicles
after immunoisolation by SDS–Triton X-100 sucrose gra-
dient centrifugation and determined the anti–caveolin-1
precipitable radioactivity in each fraction. Most of the ca-
veolin oligomers in the basolateral vesicles were found in
the middle fractions, reflecting the size range seen after
the 208C block whereas the apical vesicles, which are en-
riched in caveolin-1 (Fig. 1), had a significant proportion
of oligomers migrating to the bottom of the gradient (Fig.
8). Thus, the caveolin complexes incorporated into the
apical carriers are larger than those in the basolateral
ones, as judged by sedimentation velocity centrifugation.
The evidence for a differential distribution of caveolin-1
and -2 in apical and basolateral TGN–derived vesicles so
far is based on the immunoisolation of vesicles and subse-
quent mapping of the protein components by 2D electro-
phoresis. To obtain larger amounts of vesicles that would
allow a more quantitative analysis by Western blotting and
immunoelectron microscopy, we modified the procedure
previously established by Wandinger-Ness et al., 1990.
TGN–derived vesicles were released from semiintact cells
after disruption of the plasma membrane by hypotonic
swelling as previously described by Xu and Shields (1993).
The release of the viral glycoproteins from MDCK cells
under this conditions was reported to be regulated in the
same manner as surface transport in SLO-permeabilized
cells (Pimplikar and Simons, 1993; Müsch et al., 1996). 15–
25% of the viral marker proteins were released depending
on cytosol and the addition of energy (2.5–5.5-fold stimu-
lation, data not shown). The glycoproteins acquired termi-
nal Golgi modifications and release of proteins was not
due to fragmentation of the Golgi complex, since the
trans-Golgi marker sialyltransferase was efficiently re-
tained in the cells (data not shown). Released vesicles
were separated from the cytosol and heavy membrane
fragments by flotation through an Optiprep step gradient.
The obtained fraction predominantly contained vesicles of
80–100 nm in diameter as analyzed by negative staining
and z50% of all vesicles could be labeled with the anti-
bodies against the cytoplasmic tail of the viral proteins.
We next analyzed the distribution of the caveolins in the
vesicle popoulation by triple labeling with antibodies
against caveolin-1, -2, and antibodies against the viral gly-
coproteins (Fig. 9). VSV-G– and HA-containing vesicles
were both labeled with caveolin-1 antibodies, whereas sig-
nificant caveolin-2 labeling was restricted to basolateral
(VSV-G–containing) vesicles. Apical vesicles showed sig-
nificantly higher labeling for caveolin-1 than the basolat-
eral ones (Table I). Similar results were obtained indepen-
Figure 7. Detergent solubil-
ity of the caveolin complexes
during biosynthetic transport.
MDCK cells were pulsed for
7 min with [35S]methionine
and then chased. Cells were
lysed in 20 mM CHAPS in
TNE and the caveolin com-
plex was immunoprecipi-
tated from the supernatant
(S) and the pellet (P) and then analyzed by 3–17% SDS-PAGE
after boiling. Note that the complex is precipitated increasingly
efficiently during the chase. The autoradiograph had to be ex-
posed longer to detect pulse-labeled caveolin in the ER (no
chase, data not shown).
Figure 8. Size of the caveolin
complexes in immunoiso-
lated apical and basolateral
transport vesicles. Apical and
basolateral vesicles were iso-
lated from virally infected
MDCK cells as described in
Materials and Methods. The
immunoisolated vesicle prep-
arations were fractionated by
sedimentation velocity centrifugation and the caveolin complex
in each fraction immunoprecipitated using anti–caveolin-1 anti-
bodies. The radioactivity recovered from each fraction is indi-
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dently if the vesicles were first labeled for caveolin-1 or -2
(data not shown). This clearly demonstrates that different
caveolin complexes are efficiently included into post-Golgi
vesicles: heterooligomers of caveolin-1 and -2 in basolat-
eral vesicles and large homooligomers of caveolin-1 into
the apical vesicles.
Caveolin-2 Is Enriched in the Basolateral
Plasma Membrane
We next determined the subcellular localization of the ca-
veolins. Caveolin-1 is known to be present in both apical
and basolateral plasma membrane domains (Wandinger-
Ness et al., 1990; Dupree et al., 1993). On the other hand,
we found caveolin-2 to be strongly enriched in basolateral
vesicles. Caveolin-1 is indeed present at both the apical
and basolateral surface domains as observed in the z-sec-
tion taken from the confocal microscope (Fig. 10 A). In
contrast, caveolin-2 is enriched in the basolateral com-
pared to the apical membrane. In x, y-sections taken at dif-
ferent heights through the cell, caveolin-2 was found pref-
erentially in the basal and lateral membranes of the cell
(data not shown). To improve the fluorescence staining
and confirm that caveolin-2 is enriched at the basolateral
membrane compared to the apical membrane, we stably
transfected MDCK cells with a caveolin-2 cDNA contain-
ing a carboxy-terminal myc epitope. Also, in cells overex-
pressing tagged caveolin-2 the protein was preferentially
found in the basolateral membrane (Fig. 10 B). In the re-
gion located above the nucleus we found, in addition to the
lateral membrane staining, intracellular staining (Fig. 10 C).
Immunoelectron microscopy further substantiated the
differential localization of caveolin-1 and -2 in polarized
MDCK cells. Caveolin-1 was found in approximately
equal amounts at the apical (Fig. 11 A) and basolateral
(Fig. 11 B) membrane (0.058 6 0.006 gold particles/mm
apical and 0.071 6 0.011 gold particles/mm basolateral). At
the basolateral membrane, 61% of the gold particles was
associated with caveolae (or caveolar-like structures),
whereas no caveolae were found at the apical membrane.
Anti–caveolin-2 hardly labeled the apical membrane (data
not shown) and detected the endogenous protein prefer-
entially on the basolateral membrane (Fig. 11 C). As the
labeling for the endogenous caveolin-2 was too low to al-
low accurate quantitation, we determined the polarity in
the cell line overexpressing the protein. On the apical
membrane 2.0 6 0.2 gold particles/mm were counted,
whereas basolateral 9.6 6 1.5 gold particles/mm were
found. Similar to caveolin-1, 75% of the overexpressed ca-
veolin-2 and 54% of the endogenous protein was found in
caveolar structures. These numbers probably underesti-
mate the enrichment of the proteins in caveolae since la-
beled caveolar structures were also encountered more
than 250 nm from the plasma membrane but not included
in the quantitation.
Anti–caveolin-1 Antibodies Inhibit Apical Transport
of HA
To test whether the caveolins are functionally involved in
exocytic transport from the TGN to the cell surface, we
took advantage of the in vitro transport assays established
in our laboratory. These assays are based on monitoring
the transport of viral marker proteins in polarized SLO-
permeabilized MDCK cells and allowing the reconstitu-
tion of three biosynthetic transport routes: (a) transport of
the apical marker influenza virus HA from the TGN to the
apical cell surface, (b) transport of the basolateral marker
VSV-G from the TGN to the basolateral surface, and (c)
transport of either of the viral markers from the ER to the
Golgi complex. We have previously demonstrated that
these transport steps can be selectively inhibited by adding
specific antibodies to the permeabilized cells (for review
see Lafont et al., 1995). We tested the effect of the antica-
veolin antibodies in the transport assays. The anti–caveo-
lin-1 amino-terminal antibody had no effect on ER-to-Golgi
transport of HA, nor on the basolateral transport of VSV-G.
However, apical transport of HA was reproducibly inhib-
ited by z50% (Fig. 12). This finding suggests that anti-
body binding to the amino-terminal part of caveolin-1 spe-
cifically interferes with the function of the caveolin complex
in the apical pathway. However, binding to caveolin-1
present in basolateral vesicles is either not possible or does
not interfere with transport. Anti–caveolin-2 antibodies
were similarly tested in the transport assays but were
found to be without effects (data not shown). These data
do not prove that caveolin-1 has an essential function in
apical transport, but they clearly demonstrate that caveo-
lin-1 is in a different state in the apical vesicles as com-
pared to the basolateral vesicles.
Discussion
Our analysis of the anti–caveolin-1 immunoprecipitate by
2D gel electrophoresis revealed, for the first time, that the
caveolin complex is actually a heterooligomer of two cave-
olins, -1 and -2, with similar molecular weights but differ-
ing isoelectric points. This contradicts the previous result
by Scherer and co-workers (1996) who failed to detect ca-
Figure 9. Electron micrographs of TGN-derived vesicles labeled
for influenza virus HA (15-nm gold; A) or VSV-G (15-nm gold; B
and C) and caveolin-1 (10-nm gold) and caveolin-2 (5-nm gold).
The scale bar in C represents 100 nm.
Table I. Quantitative Analysis of Caveolin Distribution in 
Exocytic Vesicles from MDCK Cells
cav-1 cav-2 cav-1/cav-2
HA
10.0 6 0.9 11.0 6 0.8 0.5 6 0.2 19 6 4
VSV-G
3.8 6 0.4 6.9 6 0.7 4.0 6 0.6 1.6 6 0.2
The table shows one representative experiment. Routinely, gold label on 40 HA and
40 VSV-G–positive vesicles was quantitated. The number of gold particles counted
per vesicle is shown. The ratio of label for caveolin-1 and -2 was calculated for each
individual vesicle and is listed under cav-1/cav-2. Standard errors are given.Scheiffele et al. Caveolin-1 and-2 in MDCK Cells 803
veolin-2 in a high molecular weight complex. The fact that
they analyzed only the shorter form of the overexpressed
epitope-tagged caveolin-2 may account for the differences
to our results. It is possible that the use of detergent in im-
munoprecipitation may lead to artificial association of
proteins after cell lysis and coprecipitation of complexes
formed in vitro. However, we demonstrated that caveolin-1
and -2 reside in the same basolateral vesicles (Fig. 9, B and
C) and caveolin-2 was strongly enriched also in caveolar
immunoisolations performed with anti–caveolin-1 anti-
bodies in the absence of detergents (Fra, A.M., and K. Si-
mons, unpublished data), corroborating our immunolocal-
ization data that demonstrated both caveolin-1 and -2 were
present in caveolae on the basolateral membrane (Fig. 11).
Another fact that has previously escaped attention is
that caveolin-2 exists in two forms. Like caveolin-1, caveo-
lin-2 seems to use alternative translation initiation sites to
produce a and b isoforms. In caveolin-2, the longer alpha
form is clearly more abundant, whereas the a and b iso-
forms of caveolin-1 are equally prevalent.
Biosynthetic Maturation of the Caveolin Complex
One of the aims of this work was to analyze the changes
taking place in the physical state of the caveolins during
their passage from the ER to the cell surface. Earlier work
has led to the following findings: a high molecular weight
oligomer forms already in the ER and an oligomeric struc-
ture is maintained when the protein complex is trans-
ported along the biosynthetic route. Caveolin isolated
from tissues, which represents the steady-state distribution
of the protein in the TGN and caveolae, also exists as a
large complex. This oligomer is detergent-insoluble and
binds cholesterol (Monier et al., 1995; Murata et al., 1995).
The caveolin–cholesterol complex is a key structural ele-
ment in the formation of caveolae and is also potentially
important in the organization of glycosphingolipid-choles-
terol microdomains (rafts) involved in protein, and lipid
sorting (Fra et al., 1995; Parton and Simons, 1995; Ikonen
and Simons, 1997). Because neither caveolae nor rafts ex-
ist in the ER, the caveolin complex should change its be-
havior during intracellular transport. We now have sys-
tematically analyzed the biochemical characteristics of the
caveolin oligomers in pulse-chase experiments and found
the following changes.
First, although caveolin oligomers are partially formed
early in the biosynthetic route, they increase in size on
their way to the cell surface. Monomeric forms can also be
detected in the ER (although accurate quantitation of the
ratios between monomer and oligomer is not possible be-
cause the monomer is immunoprecipitated less efficiently).
We used velocity sedimentation in SDS–Triton X-100 su-
crose gradients to follow the changes during maturation of
the caveolin complex. We found that the newly synthe-
sized oligomer migrates as a 200-kD complex under these
conditions. After 1 h at 208C, the structures are between
200–400-kD and after 1 h at 378C their size increases even
further. Second, the complex becomes gradually deter-
gent-insoluble from a completely soluble ER form to an
insoluble form after transport to the Golgi complex. Third,
caveolin-2 was found to become modified by the addition
of increasing numbers of phosphate groups, the most ex-
tensive phosphorylation being found at steady state and
therefore likely to be related to the trafficking of the com-
plex between the TGN and the cell surface. Caveolin-1, on
the other hand, was not phosphorylated under these con-
ditions, although the protein can function as a substrate
for kinases (Glenney and Soppet, 1992; Mastick et al.,
1995; Li et al., 1996a). Fourth, the antibody reactivity of
the complex changes during the chase period. There is not
only a difference in the immunoprecipitation efficiencies
between the monomeric and oligomeric forms, but also
between different sizes of oligomers; the bigger the oligo-
mer the more easily it is brought down by the anti–caveo-
lin-1 amino-terminal antibody (Fig. 5). The same is true
for the anti–caveolin-2 amino-terminal antibody (data not
shown). Interestingly, we found that an anti–caveolin-1
carboxy-terminal antibody failed to immunoprecipitate
the mature complex. However, this antibody recognized
the ER form of the oligomer equally effectively as the
amino-terminal antibody (data not shown). Similarly, the
myc epitope that we introduced in the carboxy terminus of
caveolin-2 is also less acccessible at the plasma membrane
(data not shown), and antibodies against the carboxy ter-
minus of caveolin-1 fail to detect the protein on the cell
surface (Dupree et al., 1993). This suggests that a carboxy-
terminal epitope available for antibody recognition in the
ER becomes hidden during maturation of the complex.
This is in agreement with the report that the carboxy ter-
minus of caveolin is involved in oligomerization (Song et
Figure 10. Confocal immuno-
fluorescence microscopy of
caveolin-1 and -2 in filter-
grown MDCK cells. The cells
were labeled with anti–cave-
olin-1 (A) or -2 antibodies (B
and  C). Using the confocal
microscope, z-sections were
taken to show basolateral
and apical staining. They
were chosen such that the in-
tracellular staining was hardly
visualized. C shows an x, y-
section taken from the region
located above the nucleus
(B). Bar, 5 mm.The Journal of Cell Biology, Volume 140, 1998 804
al., 1997). Also, palmitoylation of cysteine residues in the
carboxy-terminal domain might interfere with antibody
recognition (Dietzen et al., 1995).
Specialized Complexes of Caveolins Exist in the Apical 
and Basolateral Traffic Routes
These data demonstrate that the newly synthesized caveo-
lins undergo dramatic changes during their transport to
the cell surface. However, the most startling finding was
the preferential routing of caveolin-2 to the basolateral
cell surface as judged by its enrichment in basolateral car-
riers and its localization on the basolateral plasma mem-
brane domain. Thus, the distributions of caveolin-1 and -2
are different over the polarized cell surfaces, caveolin-1
being present on both the apical and the basolateral sides.
Our biochemical data and the electron microscopy analy-
sis of apical and basolateral vesicles suggests that hetero-
oligomers of caveolin-1 and -2 are incorporated into the
basolateral transport vesicles in the TGN, whereas caveo-
lin-1 homooligomers are included into the apical vesicles
and transported to the apical plasma membrane domain.
This notion is in accordance with our quantitation of the
stoichiometry of the two proteins. Caveolin-1 was more
abundant than caveolin-2 and caveolin-2 antibodies failed
to coprecipitate caveolin-1 quantitatively. Moreover, we
provided biochemical evidence for two differentially be-
having caveolin oligomers. Size fractionation of the apical
and basolateral caveolin complexes from immunoisolated
vesicles revealed that the apical complexes formed larger
oligomers than the basolateral ones. This, together with
the fact that the .600-kD complexes contained less caveo-
lin-2 (Fig. 3), further supports the presence of caveolin-1
oligomers in the apical vesicles. Finally, we found that api-
cal protein transport can be disturbed by the addition of
caveolin-1 antibodies, as reflected by reduced apical deliv-
ery of HA, whereas the transport of VSV-G protein re-
cruited to basolateral vesicles occurred normally. Trans-
port of HA was, however, not inhibited by the antibody
earlier in the biosynthetic route, as ER-to-Golgi transport
was not affected.
Working Model for the Differential Roles of Caveolin-1 
and -2 in MDCK Cells
Based on these results we envisage caveolins-1 and -2 to
participate in the two post-Golgi membrane traffic routes
in MDCK cells as follows. The apical vesicles and the api-
cal plasma membrane domain contain mostly caveolin-1 in
a homooligomeric complex. The basolateral vesicles and
the basolateral plasma membrane domain, on the other
hand, contain heterooligomers of caveolin-1 and -2. The
putative homooligomers of caveolin-1, formed in the ER,
polymerize to larger structures by interactions with sphin-
golipid–cholesterol raft components during the formation
of apical transport vesicles. How the heterooligomers of
caveolin-1 and -2 become excluded from the apical vesi-
cles and included in the basolateral carriers is an open
question. They could become bound to another protein
with basolateral sorting determinants, with binding possi-
bly regulated by phosphorylation of caveolin-2.
One problem arising from the postulated differential
sorting of caveolin-1 and -2 complexes concerns the bio-
genesis of caveolae. Caveolae are present in many cell
types but in MDCK epithelial cells they are observed only
on the basolateral but not on the apical cell surface (Fig.
Figure 11. Electron micrographs showing the distribution of ca-
veolin-1 (A and B) and -2 (C) in polarized MDCK cells. In B and
C two opposing lateral membranes are shown. Caveolin-1 is
present at the apical membrane (A) and at the basolateral mem-
brane (B), where it is mainly present in caveolae (arrows). Cave-
olin-2 is mainly at the basolateral plasma membrane and its cave-
olar invaginations (C). A little further from the plasma membrane,
caveolin-2 is associated with a vesicular profile (arrowhead), which
resembles a caveolar profile deeper in the cell (C). Bar, 100 nm.
Figure 12. Effect of anti–
caveolin-1 antibodies on ER-
to-Golgi (E–G), basolateral
(BL), and apical (AP) trans-
port. Anti–caveolin-1 anti-
body N-20 (10 mg/ml) was
added to SLO-permeabi-
lized MDCK cells, and then
the transport of HA from the
ER-to-Golgi complex or from
the TGN to the apical surface
or the transport of VSV-G
from the TGN to the basolateral surface was measured. Trans-
port is expressed as percentage of cytosol-dependent transport
obtained in the absence of added antibody.Scheiffele et al. Caveolin-1 and-2 in MDCK Cells 805
11 and Parton, R.G., personal communication). On the
other hand, earlier work has demonstrated that the over-
expression of caveolin-1 is sufficient to trigger caveolar
formation in cells normally lacking both caveolin-1 and ca-
veolae (Fra et al., 1995; Li et al., 1996c). Why then do not
the caveolin-1 complexes on the apical surface form cave-
olae? One possibility is that caveolae normally are formed
by caveolin heterooligomers in which the phosphorylation
of caveolin-2 may somehow lower the concentration nec-
essary for caveolar assembly. In this case, strong overex-
pression of caveolin-1 might allow formation of caveolae
that would not be fully functional. Alternatively, func-
tional caveolae could be generated either by one or a com-
bination of several caveolin types. Additional factors on
the apical membrane could also be hindering the genera-
tion or maintenance of caveolae. Although this problem
remains to be explored, it seems most likely from our re-
sults that heterooligomers of caveolin-1 and -2 become en-
gaged in caveolar formation upon arrival to the basolat-
eral cell surface.
What then is the function of the caveolin-1 homooligo-
mers included in the apical vesicles? The most likely ex-
planation is that caveolin-1 is used to organize lipid–raft
microdomains in which rafts cluster to function as plat-
forms for apical transport. The direct association of mem-
brane proteins with rafts depends on cholesterol (Scheiffele
et al., 1997; Simons and Ikonen, 1997), and the cholesterol-
binding protein caveolin-1 might polymerize in the TGN to
organize an apical patch. Importantly, it has been demon-
strated that cholesterol depletion from cells inhibits apical
transport (Keller, P., and K. Simons, manuscript submitted
for publication) highlighting the importance of protein–
lipid interactions for the apical pathway.
In conclusion, our data offer the first indications of the
existence of functionally specialized complexes of caveo-
lins. Moreover, they suggest that in addition to caveolar
formation, caveolins can be involved in exocytic transport.
However, the presumptive function of caveolin-1 in apical
transport will require further studies. From work on other
epithelial cell types lacking caveolin-1 (FRT and Caco-2
cells; Zurzolo et al., 1994; Mirre et al., 1996), we must con-
clude that caveolin-1 cannot be a general factor for apical
sorting and delivery. Future research will have to clarify
how the molecular machinery responsible for transporting
sphingolipid–cholesterol rafts and their associated pro-
teins is constructed in different cell types.
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